Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A 2nd View: Exploring Praxis Precision Medicines’ elsunersen for Early-Onset SCN2A Developmental and Epileptic Encephalopathies

Ticker(s): PRAX, PFE, GSK, NVS, ABBV, JNJ, ESALF

Who's the expert?

Institution: Northwell Health

Division Director of Pediatric Neurology at Cohen Children's Medical Center and Director, Pediatric Neurology Service Line for Northwell Health
Treats 7 patients with SCN2A
Published over 200 peer reviewed manuscripts and written three books on the subjects of Pediatric Neurology, Epilepsy and Sleep Medicine

Interview Goal

On this call, we aim to assess the clinical relevance and potential adoption of elsunersen based on EMBRAVE study findings, including its impact on seizure reduction, unmet need in SCN2A-DEE, differentiation from current treatments, and implications for future regulatory and commercial success.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here To Join
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

8Hours Left to Join Project

Call Date: Apr 14, 2026
Call Time: 03:15 PM EDT

Wall Street Time

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here To Join
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.